NL-OMON43723已完成不适用
Proteomics analysis of cerebrospinal fluid to investigate brain involvement in pre-eclampsia - LEPRA II (liquor cerebrospinalis and pre-eclampsia)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Non pregnant women of 18 year and older
排除标准
- •Pregnant during inclusion
- •Pre-eclampsia in history
- •Auto-immune disorders
- •Oral corticosteroid use
- •Hemoglobinopathy or clotting disorder
- •Chronic hypertension or proteinuria
- •Kidney disorders
- •Neurologic disorder
研究者
相似试验
尚未招募
不适用
Proteomics analysis of cerebrospinal fluid for screening of POCD-associated moleculesThoracic aortic aneurysmJPRN-UMIN000035805Mie University20
招募中
不适用
Proteomics of cerebrospinal fluid after remote ischemic preconditioninganeurysm of the thoracic aortaJPRN-UMIN000034214Mie university hospital30
已完成
不适用
Plasma and cerebrospinal fluid concentrations treated with daily dose and high dose weekly erlotinib in non-small cell lung cancer patients with central nervous system metastasescentral nervous system metastases of non-small cell lung cancer with active EGFR mutations treated with daily dosing erlotinibJPRN-UMIN000004703Osaka City University10
已完成
不适用
An investigation on spinal fluid in patients with sciatica-type or nerve-type pain of the lower limbeuropathic lower limb painNervous System DiseasesISRCTN34007592Trinity Translational Medicine Institute12
进行中（未招募）
不适用
Cerebrospinal fluid (CSF) and plasma pharmocokinetics of liposomal cytarabine (DepoCyte®) after intrathecal administration in children with malignant brain tumors and leptomeningeal disseminatioTo measure concentrations of liposomal cytarabine in CSF and plasma over time after intrathecal administration of liposomal cytarabine in children of different age groups with a malignant brain tumor and leptomenigeal dissemination. Measurements of concentrations of cytarabine after intrathecal administration of liposomal cytarabine will help to ensure proper dosage of liposomal cytarabine in small children, avoiding neurotoxic events and subtherapeutic drug levels.EUCTR2006-004982-32-ATMedical University of Vienna, Department of Pedatrics